Case Report

Elevated Tumor‐Associated Antigen CA 19‐9 in a Patient With an Enlarged Pancreas Does It Always Imply Malignancy?

Authors: BETH A. TOLLIVER MD, BARBARA L. O'BRIEN MD

Abstract

ABSTRACT: &NA; Carbohydrate antigen 19‐9 (CA 19‐9) has been used as a serum tumor marker for adenocarcinoma of the upper gastrointestinal tract, particularly primary adenocarcinoma of the pancreas. This tumor marker has also been used to differentiate benign from malignant diseases of the pancreas. However, significant elevations of CA 19‐9 levels in the absence of pancreatic malignancy have also been reported. This case illustrates a marked elevation of CA 19‐9 due to an infectious process in a patient with a pancreatic mass suggestive of malignancy.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References